Analysts Set Aligos Therapeutics, Inc. (NASDAQ:ALGS) PT at $38.50

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) have earned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $38.50.

A number of brokerages recently issued reports on ALGS. Jefferies Financial Group upgraded shares of Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. Lake Street Capital began coverage on shares of Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 target price for the company. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Westpark Capital began coverage on shares of Aligos Therapeutics in a research report on Thursday, March 26th. They issued a “buy” rating and a $48.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Monday, April 20th.

Hedge Funds Weigh In On Aligos Therapeutics

Several large investors have recently made changes to their positions in ALGS. Woodline Partners LP bought a new position in shares of Aligos Therapeutics during the 1st quarter valued at about $2,602,000. Marshall Wace LLP bought a new position in shares of Aligos Therapeutics during the 4th quarter valued at about $2,504,000. Bank of America Corp DE boosted its position in shares of Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after purchasing an additional 216,646 shares in the last quarter. SummitTX Capital L.P. bought a new position in shares of Aligos Therapeutics during the 4th quarter valued at about $1,299,000. Finally, Verition Fund Management LLC bought a new position in shares of Aligos Therapeutics during the 4th quarter valued at about $664,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Stock Down 3.2%

ALGS stock opened at $5.11 on Tuesday. Aligos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $13.69. The firm’s 50-day simple moving average is $6.28 and its 200 day simple moving average is $7.66. The stock has a market cap of $31.63 million, a PE ratio of -0.59 and a beta of 2.25.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. The firm had revenue of $2.83 million during the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. Equities analysts forecast that Aligos Therapeutics will post -7.47 EPS for the current fiscal year.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.